Harvest Integrated Research Organization (HiRO), has announced the successful acquisition of DeltaMed Solutions, headquartered in Somerset, New Jersey. The acquisition, advised by Evercore as financial advisor, marks HiRO’s third CRO acquisition since its establishment in 2020.
DeltaMed Solutions is a global life sciences contract research organization (CRO) with a global footprint in the United States and China. DeltaMed Solutions, headquartered in New Jersey, boasts a team of industry professionals with 15-30 years of expertise in serving large to mid-sized pharmaceutical and biotechs.
HiRO is a globally oriented CRO with its headquarters in Shanghai, China. With global operations and integration capabilities, it provides a wide range of solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, end-to-end project management and clinical and medical monitoring services.
The acquisition of DeltaMed Solutions broadens HiRO’s network of clients and partners, and enhances its ability to deliver capital-efficient, expedited and customized clinical trial solutions, addressing the unmet R&D needs of pharmaceutical and biotech companies worldwide. Financial terms of the deal were not disclosed.
This acquisition follows HiRO’s recent purchase of Courante Oncology, a clinical research organization based in Excelsior, Minnesota. That transaction was announced in September 2023 and furthered HiRO’s capabilities in managing global studies and extended its presence into the U.S. market.
According to data captured in the LevinPro HC database, this acquisition represents the 13th CRO deal of 2024. There were 44 CRO transactions announced during 2023, and 41 announced during 2022.
